Tuspetinib Triple Therapy Shows High AML Response Rate at ASH
In newly diagnosed AML patients ineligible for induction, tuspetinib plus venetoclax and azacitidine delivered a 90% CR/CRh rate across...
Quetzal Launches Phase III Trial for Leukemia Drug QTX-2101
No efficacy data were disclosed. Quetzal Therapeutics has opened a global, multicenter, randomized Phase III trial of QTX-2101, an...
Novabridge Presents Expanded Phase 1 Ragistomig Data at ESMO
NovaBridge’s Phase 1 expansion of ragistomig, a PD-L1 × 4-1BB bispecific, reports responses in patients previously non-responsive to checkpoint...
PainReform Starts Phase II Trial for OcuRing-K Eye Therapy
Preclinical work and a Phase 1 evaluation of OcuRing-K reported reductions in post-cataract pain and inflammation with lower total...
Empaveli Positive Phase 3 VALIANT Results Published in NEJM
Topline: In the Phase 3 VALIANT trial for C3 glomerulopathy and primary IC-MPGN, pegcetacoplan cut proteinuria by 68% versus...
Significant ALS Biomarker Results Support Clene’s CNM-Au8
CNM-Au8 produced statistically significant declines in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) with signals that track...
CARES-310 Study Final Analysis Published in The Lancet
Camrelizumab plus rivoceranib delivered a median overall survival of 23.8 months versus 15.2 months on sorafenib in first-line unresectable...
Inspira’s Lab Breakthrough Accelerates Blood Diagnostics Tech
Inspira Technologies is expanding its core blood laboratory operations, moving into a larger facility with upgraded instrumentation and plans...
First Patient Dosed in Crinetics’ Neuroendocrine Tumor Trial
Crinetics has dosed the first patient in BRAVESST2, a first-in-human Phase 1/2 study of CRN09682 in metastatic or locally...
Relmada Presents NDV-01 Phase 2 Urologic Oncology Data
NDV-01, a sustained-release intravesical gemcitabine/docetaxel formulation, has reported a 92% complete response at any time point at nine months...